Hepatitis C testing for people who inject drugs in the United Kingdom: Why is uptake so low?

References

• Aitken CK, Kerger M, Crofts N. Peer-delivered hepatitis C testing and counselling: A means of improving the health of injecting drug users. Drug and Alcohol Review 2002; 21: 33–37
   PubMed Web of Science ®Google Scholar
• Car J, Gurol-Urganci I, de Jongh T, Vodopivec-Jamsek V, Atun R. Mobile phone messaging reminders for attendance at healthcare appointments. Cochrane Database of Systematic Reviews 2012; 7: CD007458
   PubMed Web of Science ®Google Scholar
• Craine N, Parry J, O’Toole J, D’Arcy S, Lyons M. Improving blood-borne viral diagnosis; clinical audit of the uptake of dried blood spot testing offered by a substance misuse service. Journal of Viral Hepatitis 2009; 16: 219–222
   PubMed Web of Science ®Google Scholar
• Craine N, Walker M, Carnwath T, Klee H. Hepatitis C testing and injecting risk behaviour: The results of a UK based pilot study. The International Journal of Drug Policy 2004; 15: 115–122
   Google Scholar
• Day CA, White B, Thein HH, Doab A, Dore GJ, Bates A, , Maher L, et al. Experience of hepatitis C testing among injecting drug users in Sydney, Australia. AIDS Care 2008; 20: 116–123
   PubMed Web of Science ®Google Scholar
• Department of Health. Drug Misuse and Dependence: UK Guidelines on Clinical Management. Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive, London 2007
   Google Scholar
• European Association for Study of the Liver: EASL Clinical Practice Guidelines. Management of hepatitis C virus infection. Journal of Hepatology 2011; 55: 245–264
   PubMed Web of Science ®Google Scholar
• Glaser BG, Strauss AL. The discovery of grounded theory: Strategies for qualitative research. Aldine, Chicago, IL 1967
   Google Scholar
• Harris M, Rhodes T. Venous access and care: Harnessing pragmatics in harm reduction for people who inject drugs. Addiction 2012; 107: 1090–1096
   PubMed Web of Science ®Google Scholar
• Harris M, Rhodes T. Injecting practices in sexual partnerships: HCV transmission potentials in a ‘risk equivalence’ framework. Drug and Alcohol Dependence 2013; 3: 617–623
   Google Scholar
• Harris M, Rhodes T, Martin A. Taming systems to create enabling environments for HCV treatment: Negotiating trust in the drug and alcohol setting. Social Science and Medicine 2013; 83: 19–26
   PubMed Web of Science ®Google Scholar
• Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, Esmat G, et al. The state of hepatitis B and C in Europe: Report from the hepatitis B and C summit conference. Journal of Viral Hepatitis 2011; 18: 1–16
   PubMed Web of Science ®Google Scholar
• Health Protection Agency: Hepatitis C in the UK: 2012 Report. Health Protection Agency 2012
   Google Scholar
• Hickman M, McDonald T, Judd A, Nichols T, Hope V, Skidmore S, Parry JV. Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: A cluster randomized controlled trial. Journal of Viral Hepatitis 2008; 15: 250–254
   PubMed Web of Science ®Google Scholar
• Iversen J, Maher L. Australian Needle and Syringe Program National Data Report 2007–2011. The Kirby Institute, University of New South Wales, Sydney 2012
   Google Scholar
• Khaw FM, Stobbart L, Murtagh MJ. ‘I just keep thinking I haven’t got it because I’m not yellow’: A qualitative study of the factors that influence the uptake of Hepatitis C testing by prisoners. BMC Public Health 2007; 7: 98
   PubMedGoogle Scholar
• Kirwan P, Evans B, Brant L. Hepatitis C and B testing in English prisons is low but increasing. Journal of Public Health 2011; 33: 197–204
   PubMed Web of Science ®Google Scholar
• Lally MA, Montstream-Quas SA, Tanaka S, Tedeschi SK, Morrow KM. A qualitative study among injection drug using women in Rhode Island: Attitudes toward testing, treatment, and vaccination for hepatitis and HIV. AIDS Patient Care and STDs 2008; 22: 53–64
   PubMed Web of Science ®Google Scholar
• Lazarus JV, Shete PB, Eramova I, Merkinaite S, Matic S. HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management. International Journal of Drug Policy 2007; 18: 426–432
   PubMed Web of Science ®Google Scholar
• Lim EJ, Haar J, Morgan J. Can text messaging results reduce time to treatment of Chlamydia trachomatis?. Sexually Transmitted Infections 2008; 84: 563–564
   PubMed Web of Science ®Google Scholar
• Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. Journal of Hepatology 2011; 54: 1137–1144
   PubMed Web of Science ®Google Scholar
• Mason S, Watts A, Sheils S, Koorey D. Improving access to HCV treatment: External jugular venepuncture can overcome problems with difficult venous access. The International Journal of Drug Policy 2007; 18: 433–436
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence: Technology Appraisal Guidance 75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic HCV. London: National Institute for Clinical Excellence; 2004
   Google Scholar
• National Institute for Health and Clinical Excellence. Drug misuse: Psychosocial interventions. National Institute for Health and Clinical Excellence; 2007
   Google Scholar
• Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. The Lancet 2011; 378: 571–583
   PubMed Web of Science ®Google Scholar
• Paterson BL, Backmund M, Hirsch G, Yim C. The depiction of stigmatization in research about hepatitis C. International Journal of Drug Policy 2007; 18: 364–373
   PubMed Web of Science ®Google Scholar
• Petry NM. Contingency management treatments. The British Journal of Psychiatry 2006; 189: 97–98
   PubMed Web of Science ®Google Scholar
• Philpott A, Knerr W, Boydell V. Pleasure and prevention: When good sex is safer sex. Reproductive Health Matters 2006; 14: 23–31
   PubMed Web of Science ®Google Scholar
• Race K. The use of pleasure in harm reduction: Perspectives from the history of sexuality. The International Journal of Drug Policy 2008; 19: 417–423
   PubMed Web of Science ®Google Scholar
• Radcliffe P, Stevens A. Are drug treatment services only for ‘thieving junkie scumbags’? Drug users and the management of stigmatised identities. Social Science and Medicine 2008; 67: 1065–1073
   PubMed Web of Science ®Google Scholar
• Rhodes T, Coomber R. Qualitative methods and theory in addictions research. Addiction research methods, PG Miller, J Strang, PM Miller. Blackwell, Oxford 2010; 59–78
   Google Scholar
• Rhodes T, Davis M, Judd A. Hepatitis C and its risk management among drug injectors in London: Renewing harm reduction in the context of uncertainty. Addiction 2004; 99: 621–633
   PubMed Web of Science ®Google Scholar
• Richards M. Extent and causes of international variations in drug usage. Department of Health, London 2010
   Google Scholar
• Semer N, Ellison J, Mansell C, Hoika L, MacDougall W, Gansky SA, Walsh MM. Development and evaluation of a tobacco cessation motivational program for adolescents based on physical attractiveness and oral health. Journal of Dental Hygiene 2005; 79: 9
   Google Scholar
• Siedner MJ, Haberer JE, Bwana MB, Ware NC, Bangsberg DR. High acceptability for cell phone text messages to improve communication of laboratory results with HIV-infected patients in rural Uganda: A crosssectional survey study. BMC Medical Informatics and Decision Making 2012; 12: 56
   PubMed Web of Science ®Google Scholar
• Strang J, Keaney F, Butterworth G, Noble A, Best D. Different forms of heroin and their relationship to cook-up techniques: Data on, and explanation of, use of lemon juice and other acids. Substance Use & Misuse 2001; 36: 573–588
   PubMed Web of Science ®Google Scholar
• Strauss S, Munoz-Plaza CE, Tiburcio NJ, Astone-Twerell J, Des Jarlais DC, Gwadz M, , Rosenblum A, et al. Barriers and facilitators to undergoing Hepatitis C virus (HCV) testing through drug treatment programs. Journal of Drug Issues 2008; 38: 1161–1185
   Web of Science ®Google Scholar
• Swan D, Long J, Carr O, Flanagan J, Irish H, Keating S, McKiernan S, et al. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: A qualitative exploration. AIDS Patient Care and STDs 2010; 24: 753–762
   PubMed Web of Science ®Google Scholar
• Treloar CJ, Hopwood MN, Loveday SK. Hepatitis C-related discrimination in healthcare. Report of the Third Australasian Conference on Hepatitis C, Melbourne, March 202. The Medical Journal of Australia 2002; 177: 233–234
   PubMedGoogle Scholar
• Tripathi A, Duffus WA, Kissinger P, Brown TJ, Gibson JJ, Mena LA. Delivering laboratory results by text message and e-mail: A survey of factors associated with conceptual acceptability among STD clinic attendees. Telemedicine Journal and E-Health 2012; 18: 500–506
   PubMed Web of Science ®Google Scholar
• White B, Day C, Thein HH, Doab A, Bates A, Holden J, , Maher L, et al. Acceptability of hepatitis C virus testing methods among injecting drug users. Drug and Alcohol Review 2008; 27: 666–670
   PubMed Web of Science ®Google Scholar
• Winter R, Nguyen O, Higgs P, Armstrong S, Duong D, Thach ML, , Hellard M, et al. Integrating enhanced hepatitis C testing and counselling in research. The International Journal of Drug Policy 2008; 19: 66–70
   PubMed Web of Science ®Google Scholar
• World Health Organisation Regional Office for Europe: Barriers and facilitators to hepatitis C treatment for people who inject drugs: A qualitative study. Copenhagen: World Health Organisation Regional Office for Europe; 2012
   Google Scholar